Pfizer announced that its earnings rose to $3.56 billion in the first quarter, compared to $3.12 billion in the same period last year. Revenue rose from $12.78 billion to $12.91 billion.
Merck & Co (Mersha East) announced that its first-quarter earnings fell to $736 million, compared to $1.55 billion in the same period last year. The company's costs associated with Eisai are $1.4 billion. Revenue rose from $9.43 billion to $10.04 billion.
Johnson & Johnson, a pharmaceutical and consumer goods company, announced its first-quarter results. The company's net profit fell to 4.37 billion US dollars, compared with 4.42 billion US dollars in the same period last year. Revenue rose 12.6% to $20.01 billion, with consumer, pharmaceutical and medical device revenues both rising and exceeding expectations.
AbbVie announced that its first-quarter profit and revenue exceeded expectations. Earnings for the quarter rose to $2.78 billion, compared to $1.71 billion in the same period last year. Revenue rose from $6.54 billion to $7.93 billion. Sales of Xiu Mei Le, Imbruvica, Lupron, Creon, Synagis, AndroGel, Duodopa and Sevoflurane were higher than expected, while sales of Synthroid and Kaletra were less than expected.
Eli Lilly and Co, the pharmaceutical company, turned its net profit to $1.22 billion in the first quarter, compared with a loss of $110.8 million in the same period last year. Revenue rose from $5.23 billion to $5.7 billion.
Amgen (Agen) announced a profit of $2.31 billion in the first quarter, compared to $2.07 billion in the same period last year. After a one-time project adjustment, the profit was 2.46 billion US dollars, compared with 2.33 billion US dollars in the same period of the previous year. Sales rose 2% to $5.55 billion from $5.46 billion in the previous year.
Bristol-Myers Squibb announced that its corporate earnings fell to $1.49 billion in the first quarter, compared to $1.57 billion in the same period last year. Revenue rose from $4.93 billion to $5.19 billion. Sales at Opdivo, Eliquis and Orencia exceeded expectations, while sales at Sprycel, Yervoy and Empliciti were lower than expected.
Gilead Sciences, the pharmaceutical company, announced that its net profit for the first quarter was $1.54 billion, compared with $2.7 billion for the same period last year. Revenue fell from $6.51 billion in the previous year to $5.09 billion.
Celgene announced that its earnings in the first quarter fell to $864 million, compared to $932 million in the same period last year. Revenue rose from $2.962 billion to $3.538 billion. Sales of Revlimid, Pomalyst, Otezla, Abraxane and Vidaza were higher than expected. The company completed the acquisition of biotech company Juno in March.
Biogen Inc. announced that its first-quarter earnings rose to $1.2 billion, compared to $748 million in the same period last year. Revenue rose from $2.81 billion to $3.13 billion.
Valeant Pharmaceuticals International reported a loss of $2.69 billion in the first quarter and a profit of $628 million in the same period last year. Revenue fell from $2,109 million to $1.995 billion. Branded prescription drugs and diversified US sales were higher than expected, while Bausch & Lomb sales were lower than expected.
F. Hoffmann-La Roche Ltd released its first quarter results. The quarterly group sales were 13.583 billion Swiss francs, compared with 12.942 billion Swiss francs in the same period last year. Among them, the pharmaceutical business sales of 10.672 billion Swiss francs in the same period, compared with 10.177 billion Swiss francs in the same period last year. Diagnostic business sales for the quarter were 2.911 billion Swiss francs, compared with 2.675 billion Swiss francs for the same period last year.
Novartis AG released its earnings report. The company's first quarter net sales of 12.694 billion US dollars, compared with 11.539 billion US dollars in the same period last year. Net profit for the quarter was $2.028 billion, compared to $1.665 billion for the same period last year.
Sanofi SA's first quarter results. Net sales for the quarter were 7.988 billion euros, compared with 8.653 billion euros in the same period last year. Sanofi has completed the acquisition of Bioverativ in the first quarter. Net profit for the quarter was €1,016 million, compared to €5.696 billion for the same period last year.
GlaxoSmithKline (GSK) announced that it achieved sales of 7.2 billion pounds in the first quarter of 2018, a 2% decline based on the real exchange rate and a 4% increase based on a constant exchange rate. Prescription drug sales were 4 billion pounds, vaccine sales were 1.2 billion pounds, and consumer health products sales were 2 billion pounds.
AstraZeneca PLC announced its first quarter results for 2018. Total revenue for the quarter was $5.178 billion, a decrease of 9% year-on-year. Operating profit was $896 million, a year-on-year decrease of 47%.
Bayer's sales in the first three months of 2018 increased. In the first quarter, the Group's sales increased by 2.0% (after adjusting the exchange rate and asset portfolio: a decrease of 5.6%) to reach 9.138 billion euros. Profit before interest, taxes, depreciation and amortization, excluding special items, fell 5.2% to 2.896 billion euros. Earnings before interest and taxes fell 4.8% to 2.31 billion euros. Net income fell 6.2% to 1.954 billion euros. Prescription drug sales reached 4.075 billion euros, self-care products (health consumer goods) sales of 1.409 billion euros, agricultural business (crop science division) sales of 2.861 billion euros, animal health business sales of 414 million euros EUR.
Merck KGaA of Germany announced its first quarter results for 2018. Net sales for the quarter were €3.691 billion, a decrease of 4.4% from €3.861 billion in the same period last year. The quarterly EBITDA margin was 946 million euros, a decrease of 21.4% from the 1.003 billion euros in the same period last year. The net sales of the health care business was 1.640 billion euros, the net sales of the life sciences business was 1.487 billion euros, and the net sales of the materials business was 564 million euros.
Allergan announced that its net loss for the first quarter narrowed to $332.5 million, compared to $2.63 billion in the same period last year. Revenue rose 2.8% to $3.67 billion, with international brand revenues better than expected, offsetting a small marginal decline in US professional treatment income, while US regular drug revenues were in line with expectations.
Shire plc announced its first quarter results for 2018. Total revenue for the quarter was $3.766 billion, an increase of 5% year-on-year. Net profit for the quarter was $551 million, a year-on-year increase of 47%.
Mylan announced that its corporate earnings rose to $87.1 million in the first quarter, compared to $66.4 million in the same period last year. Revenue fell from $2.72 billion to $2.68 billion. Net sales in North America declined year-on-year, with sales of branded products such as EpiPen dropping significantly.
Novo Nordisk announced its first quarter results for 2018. Sales fell by 5% in Danish Krone to DKK 26.9 billion. Sales in the field of diabetes treatment and obesity fell by 5% to DKK 22.6 billion. Sales in the biopharmaceutical sector fell by 8% to DKK 4.3 billion. Operating profit reported in Danish Krone fell by 8% to DKK 12.4 billion. Net profit increased by 6% to DKK 10.8 billion.
Teva Pharmaceutical Industries announced that its first-quarter earnings rose to $1.01 billion, compared to $580 million in the same period last year. Revenue fell from $5.65 billion to $5.07 billion.
Takeda Pharmaceutical announced its results for the fiscal year 2017 (ending March 31, 2018).
Astellas Pharma Inc. announced its results for the fiscal year 2017 (ending March 31, 2018). Annual sales were 130.3 billion yen, a decrease of 0.9% from the previous year's 131.7 billion yen. The core operating profit for the year was 268.7 billion yen, a decrease of 2.1% from the 274.6 billion yen in the previous year. The core profit for the year was 204.3 billion yen, a decrease of 4.2% from the 213.3 billion yen in the previous year.
The Daiichi Sankyo Company, Limited announced its results for the fiscal year 2017 (ending March 31, 2018). The annual revenue was 960.2 billion yen, an increase of 0.5% from the previous year's 955.1 billion yen. The annual operating profit was 76.3 billion yen, a decrease of 14.2% from the previous year's 88.9 billion yen. The net profit for the year was 60.3 billion yen, an increase of 12.7% over the previous year's 53.5 billion yen.
Medtronic announced that its fourth-quarter (as of April 27) net profit rose to $1,460 million, compared to $1,163 million in the same period last year. Revenue rose 2.9% to $8.144 billion. US revenues were $5.187 billion, accounting for 52% of total revenue.
In mid-March this year, just listed Siemens Medical Solutions (Siemens Healthineers) released its second quarter (ended March 31) earnings report. The financial report showed that the company's operating profit for the quarter fell year-on-year due to the impact of the listing expenses. The company's second-quarter operating profit fell to 457 million euros, down 16% year-on-year. This data includes €103 million in expenses related to the company's initial public offering on March 18. Revenue for the second quarter fell 5% year-on-year to 3.22 billion euros. Adjusted net profit for the second quarter reached 428 million euros, a year-on-year increase of 26%.
Health technology company Philips (Royal Philips NV) released its first quarter results. Sales for the quarter were 3.942 billion euros, compared to 4.035 billion euros in the same period last year. Net profit for the quarter was €124 million, compared to €259 million for the same period last year.
Healthcare and research and development company Abbott Laboratories announced first-quarter results. Net profit fell to $418 million, compared to $419 million in the same period last year. Revenue rose 16.7% to $7.39 billion, with sales in the nutrition and diagnostics business exceeding expectations, while existing drug revenues were slightly below expectations.
Medical technology company Becton (Dickinson and Company) announced its second-quarter results as of March 31, 2018. Revenue for the quarter was $4.222 billion, compared to $2.969 billion in the same period last year, an increase of 42.2% year-on-year. This significant increase in quarterly revenue, mainly due to revenue recognized in the post-acquisition Bard Medical Technology (C. R. Bard, Inc.). The net loss for the quarter was $50 million, compared with a net profit of $344 million for the same period last year.
Danaher Corporation released its first quarter results. Sales for the quarter were $4.695 billion, compared to $4.206 billion for the same period last year. Net profit for the quarter was $567 million, compared to $506 million in the same period last year.
STRYKER CORPORATION announced its first quarter results. Net sales for the quarter were $3.241 billion, an increase of 9.7% from $2.955 billion in the same period last year. Net profit for the quarter was $443 million, compared to $444 million for the same period last year.
LabCorp announced its first quarter results. Revenue for the quarter was $2.848 billion, compared to $2.414 billion for the same period last year. Net profit for the quarter was $173 million, compared to $183 million for the same period last year.
BAXTER INTERNATIONAL released its first quarter results. Net sales for the quarter were $2.677 billion, an increase of 8% from $2.475 billion in the same period last year. Net profit for the quarter was $389 million, an increase of 43% from $272 million in the same period last year.
Boston Scientific released its first quarter results. Net sales for the quarter were $2.379 billion, compared to $2.16 billion for the same period last year. Net profit for the quarter was $298 million, compared to $290 million for the same period last year.
Zimmer Biomet Holdings Inc. released its first quarter results. Net sales for the quarter were $2.018 billion, compared to $1.972 billion for the same period last year. Net profit for the quarter was $175 million, compared to $299 million for the same period last year.
Quest Diagnostics released its first quarter results. Net revenue for the quarter was $1.884 billion, an increase of 3.7% from $1.817 billion in the same period last year. Net profit for the quarter was $177 million, an increase of 8.2% from $164 million in the same period last year.
Medical supplies distributor McKesson announced a fourth-quarter (as of March 31) net loss of $1,146 million, compared with a profit of $3.588 billion in the same period last year. The December tax reform boosted the company's earnings, but the company's retail operations in Europe and Canada generated non-cash goodwill and long-term asset impairment losses. Revenue rose from $48.7 billion to $51.6 billion.
AmerisourceBergen announced that its earnings in the second quarter fell to $287.5 million, compared to $411.5 million in the same period last year. Revenue rose from $37.15 billion to $41.03 billion.
Express Securities Holdings, Inc. announced that its net profit for the first quarter was $623.2 million, compared with $546.3 million for the same period last year. Revenue rose from $24.65 billion in the previous year to $24.77 billion.
Cardinal Health announced that its corporate earnings fell to $255 million in the third quarter, compared to $381 million in the same period last year. Revenue rose from $31.8 billion to $33.6 billion.
CVS Health Corp announced that its first-quarter earnings rose to $998 million, compared to $953 million in the same period last year. Revenue rose from $44.51 billion to $45.69 billion.
The chain pharmacy Walgreens Boots Alliance announced its second-quarter results as of February 28, 2018. Sales for the quarter were $33.21 billion, compared to $29.446 billion for the same period last year. Net profit for the quarter was $1.339 billion, compared to $1.06 billion for the same period last year.
Rite Aid announced a net profit of $767 million in the fourth quarter, compared with a loss of $21 million in the same period last year. Revenue fell from $5.88 billion to $5.661 billion.
HCA Holdings Inc announced that its first-quarter earnings rose to $1.28 billion, compared with $777 million in the same period last year, and assets sold for $405 million, while employee equity incentives generated $92 million in tax benefits. Revenue rose from $10.62 billion to $11.42 billion.
Tenet Healthcare Corporation announced that its first-quarter profit was $99 million, compared with a net loss of $53 million in the same period last year. Revenue fell from $4.8 billion in the previous year to $4.7 billion.
Adult diapers are disposable urinary incontinence products, one of the adult care products, and a disposable diaper mainly suitable for incontinent adults. Most products are flaky and shorts type. Use adhesive sheets to connect into a pair of shorts. The adhesive sheet also has the function of adjusting the waist size so as to fit different fat and thin body shapes. Generally, the structure of diapers is divided into three layers from the inside to the outside. The inner layer is close to the skin and made of non-woven fabric; the middle layer is water-absorbent fluff pulp, added with polymer water-absorbing agent; the outer layer is an impermeable breathable film.
Adult Briefs,Depends Adult Diapers,Adult Diapers For Sale,Adult Disposable Diapers
Shandong Kangshun Daily Products Co., Ltd , https://www.centurybenifit.com